Company attributes
Industry
Location
Founder
Legal Name
OrphoMed Inc.
Number of Employees (Ranges)
11 – 500
Email Address
glb@orphomed.com0
Full Address
50 Francisco St, San Francisco, California 94133, US
Investors
Founded Date
2014
0Total Funding Amount (USD)
39,000,000
Latest Funding Round Date
May 2017
Board of Directors
Latest Funding Type
Country
Other attributes
Company Operating Status
Active
Public/Private
Private0
OrphoMed is a clinical-stage biotechnology company with a proprietary dimer therapeutics platform. The company is focused on developing treatments for patients with gastrointestinal disorders.
In May 2017, OrphoMed raised $39 million Series A financing. The round was led by New Enterprise Associates, and co-led by existing seed investor Takeda Ventures, Inc., with participation from other prior investors: Pappas Capital, through its newest fund, Pappas Ventures V; Relativity Healthcare Partners and the Mario Family Fund.
The capital will be used to advance the clinical development of OrphoMed's lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
